Cannabinoid and Protocatechuic Acid Composition for Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammation lack effective combinations of cannabinoids and antioxidants that can synergistically address inflammation and oxidative stress, with cannabinoids like CBD having unknown pharmacology and PCA having established anti-inflammatory properties but different administration routes and bioavailability.
Innovation Solution
A composition comprising a therapeutically effective amount of a cannabinoid, preferably CBD, combined with protocatechuic acid (PCA), administered simultaneously or through different routes to maximize bioavailability and efficacy, including in beverages and topical applications, to treat inflammation and oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids like CBD are used to treat inflammation, then anti-inflammatory effects are achieved, but the pharmacology is unknown and bioavailability varies with administration routes
Solution Approach 1:
The patent uses protocatechuic acid as an intermediary substance to enhance and standardize the anti-inflammatory effect of cannabinoids. PCA has well-established pharmacology and predictable bioavailability, serving as a mediator that reduces the uncertainty associated with cannabinoid pharmacology while maintaining their therapeutic benefits.
Solution Approach 2:
The invention creates a composite therapeutic composition combining cannabinoids (with unknown pharmacology) and protocatechuic acid (with established pharmacology). This composite approach allows the predictable component (PCA) to compensate for the uncertainty of the unpredictable component (cannabinoids), achieving reliable anti-inflammatory effects.
2Productivity
If different administration routes are used for cannabinoids and PCA, then bioavailability can be optimized, but the treatment protocol becomes more complex
Solution Approach 1:
The patent merges multiple administration routes into a single coordinated protocol. By administering cannabinoids orally and PCA intravenously in a synchronized manner (within 30 minutes of each other), the invention combines the bioavailability advantages of different routes while simplifying the overall treatment protocol through standardized timing and coordination.
3Reliability
If higher doses of CBD are administered to achieve therapeutic effects, then anti-inflammatory efficacy improves, but side effects may increase
Solution Approach 1:
The patent applies partial action by using lower doses of CBD than would be required for monotherapy, supplemented by PCA to achieve the full therapeutic effect. This allows achieving sufficient anti-inflammatory efficacy with sub-maximal CBD doses, thereby reducing potential side effects while maintaining treatment effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of CBD and PCA provides enhanced anti-inflammatory and antioxidant effects, reducing pain, inflammation, and oxidative stress, with minimal side effects, and can be administered through various routes to optimize bioavailability and therapeutic benefits.
Implementation Method 1
The combination of CBD and PCA provides enhanced anti-inflammatory and antioxidant effects, reducing pain, inflammation, and oxidative stress
Implementation Method 2
The combination of CBD and PCA provides enhanced anti-inflammatory and antioxidant effects, reducing pain, inflammation, and oxidative stress
Data Source
AI summary
The disclosure is directed to a beverage sachet including a powder which includes protocatechuic acid, an electrolyte, and a sweetener. The sachet can further include a cannabinoid. The cannabinoid may be cannabidiol. The electrolyte may include sodium chloride salt or monopotassium phosphate salt. The sachet may further include vitamin C, vitamin D, a B vitamin, magnesium, or calcium. The sweetener may include sucrose, glucose, dextrose, maltodextrins, or fructose. The disclosure also includes a beverage including protocatechuic acid and a cannabinoid. The cannabinoid may be cannabidiol. The beverage may be a sports beverage including sweeteners and electrolytes. The beverage may be a health beverage including a fruit, a vegetable, vitamin C, vitamin D, a B vitamin, magnesium, or calcium.